Brought to you by 
Grunenthal gets lesinurad rights in Europe and Latin American from AZ
15 Sep 2017
Executive Summary
AstraZeneca PLC granted Grunenthal GMBH exclusive rights throughout Europe and Latin America to develop and commercialize Zurampic (lesinurad), a urate transporter 1 (URAT1) inhibitor approved to treat hyperuricemia in adults with uncontrolled gout. Grunenthal also gets rights to an allopurinol/lesinurad fixed-dose combination in Phase III trials for the same indication.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Grunenthal gets lesinurad rights in Europe and Latin American from AZ
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice